A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies. - Lynce, Filipa; Wang, Hongkun; Petricoin, Emanuel F.; Pohlmann, Paula R.; Smaglo, Brandon; Hwang, Jimmy; He, Aiwu R.; Subramaniam, Deepa S.; Deeken, John; Marshall, John; Pishvaian, Michael J. (Cancer Chemotherapy & Pharmacology, 2019)